补充Pycnogenol®以缓解切除术后的症状
Gianni Belcaro1,2, Roberto Cotellese3, Marcello Corsi4,5
1Irvine3 and Nicolaides Labs, Department of Circulation Sciences, Spoltore, Pescara, Italy - cardres@abol.it.
Minerva surgery
|June 7, 2024
概括
补充Pycnogenol®显著降低了瘤切除术后的疼痛,不适和便秘. 这种天然补充剂改善了接受手术治疗的患者的生活质量和康复时间.
科学领域:
- 血管外科 血管外科
- 植物疗法 植物疗法
- 术后康复 术后康复
背景情况:
- 是一种普遍的疾病,会引起严重的不适和降低生活质量,通常需要像切除性切除术 (EH) 这样的手术干预.
- 手术后的症状,包括,疼痛和肠道习惯的改变,通常会使瘤切除术后的恢复复杂化.
- 标准管理通常包括食纤维,炼和尽量减少压力以防止复发.
研究的目的:
- 为了评估Pycnogenol®在减轻切除性出血栓切除术后常见的术后症状方面的疗效.
- 评估Pycnogenol®补充剂对患者生活质量和手术后恢复日常活动的影响.
主要方法:
- 一项注册研究涉及38名接受首次切除性出血切除术的患者.
- 参与者接受了Pycnogenol® (150 mg/天) 加上标准管理 (SM) 或单独SM (对照组) 在手术前和后一个月.
- 手术后的疼痛,不适,便秘,生活质量,出血和恢复活动都被系统地得分并在各组之间进行了比较.
主要成果:
- 与对照人群相比,在手术后10天和30天补充Pycnogenol®的患者报告疼痛,不适和便秘的得分明显较低.
- 在Pycnogenol®组中观察到更高的生活质量得分和更快地恢复日常活动.
- 在Pycnogenol®组中,在手术后的第10天和第30天之间,对止痛药的需要显著减少.
结论:
- 在这项试点研究中,Pycnogenol®在经过切除术后的术后症状的管理和预防方面表现出有效性.
- 该补充剂似乎可以减少水和围胀,有助于更舒适和受控的恢复.
- 需要对更大的队列和各种手术方法进行进一步的研究,以证实这些有前途的发现.
相关概念视频
01:21Drugs for Treatment of Constipation-Predominant IBS
157
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
157
01:17Drugs for Treatment of Diarrhea-Predominant IBS
159
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
159
01:26Endoscopic Procedures IV: Sigmoidoscopy and Laproscopy
72
Sigmoidoscopy and laparoscopy are distinct medical procedures that enable physicians to internally inspect different parts of the GI tract. Although they serve different purposes, each is essential for diagnosing and, in some cases, treating various medical conditions.
Sigmoidoscopy
Sigmoidoscopy is a diagnostic procedure that uses a flexible sigmoidoscope equipped with a light source and camera to examine the rectum and sigmoid colon. The procedure involves inserting the tube through the anus...
Sigmoidoscopy
Sigmoidoscopy is a diagnostic procedure that uses a flexible sigmoidoscope equipped with a light source and camera to examine the rectum and sigmoid colon. The procedure involves inserting the tube through the anus...
72
01:21Inflammatory Bowel Disease V: Surgical Management
139
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
139
01:25Endoscopic Procedures II: Colonoscopy
82
The colon, or large intestine, is the final segment of the digestive system. Its primary functions include absorbing water and vitamins produced by gut bacteria and transforming waste from liquid to solid to form stool. In adults, the large intestine is approximately 5 feet long and consists of four main sections:
82
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
167
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167